Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating

• US 8,778,376 B2
• Filed: 06/09/2006
• Issued: 07/15/2014
• Est. Priority Date: 06/09/2006
• Status: Expired due to Fees

• Current Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Hossainy, Syed F. A., Trollsas, Mikael, Glauser, Thierry, Tang, Yiwen
• Primary Examiner(s): Naff, David M
• Application Number:
  US11/449,896
• Publication Number:
  US 20070286885A1
• Time in Patent Office: 2,958 Days
• US Class Current: 424/423
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61L 2300/25 Peptides having up to 20 amino acids in a defined sequence
• CPC Class Codes: A61L 2420/02 Methods for coating medical devices
• CPC Class Codes: A61L 27/227 Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 31/047 Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: B05D 3/007 : After-treatment
• CPC Class Codes: C07K 14/001 : by chemical synthesis
• CPC Class Codes: C08H 1/00 : Macromolecular products derived from proteins food proteins A23; glue, gelatine C09H
• CPC Class Codes: Y10T 428/3154 : Of fluorinated addition polymer from unsaturated monomers
• CPC Class Codes: Y10T 428/31909 : Next to second addition polymer from unsaturated monomers

Abstract

A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided.

Claims

1. A block copolymer comprising an elastin pentapeptide block (A) and a hydrophilic block (B),

wherein the elastin pentapeptide is VGVPG (SEQ ID NO:

1),

wherein the A and B blocks are linked by a biodegradable polymer linkage;

wherein block B comprises a synthetic polymer selected from polyethylene glycol (PEG), PVP (poly vinylpyrrolidinone), polyacrylamide, poly(PEG acrylate), poly (HEMA), poly(acrylic acid) or combinations of these; and

wherein the synthetic polymer comprises phosphoryl choline (PC) pendant groups.

2. The block copolymer of claim 1, which is an ABA triblock copolymer.

3. The block copolymer of claim 1, wherein the hydrophilic block further comprises lysine.

4. The block copolymer of claim 2, wherein the hydrophilic block further comprises lysine.

5. The block copolymer of claim 2, wherein the synthetic polymer further comprises poly(ethylene glycol) (PEG) pendant groups.

6. The block copolymer of claim 2, wherein the hydrophilic block further comprises a natural polymer.

7. The block copolymer of claim 1, wherein the synthetic polymer further comprises poly(ethylene glycol) (PEG) pendant groups,

wherein the PC or PEG is conjugated to the block copolymer via lysine in the hydrophilic block.

8. The block copolymer of claim 1, wherein the synthetic polymer is selected from PEG, PVP (poly vinylpyrrolidinone), polyacrylamide, poly(PEG acrylate), poly (HEMA), or poly(acrylic acid).

9. The block copolymer of claim 6, wherein the natural polymer is selected from collagen, hyaluronic acid, alginate or combinations of these.

10. The block copolymer of claim 1, further comprising a sequence selected from RGD, cRGD, SIKVAV, CNP, YIGSRG, mimetics of these, or combinations of these.

11. The block copolymer of claim 2, further comprising a sequence selected from RGD, cRGD, SIKVAV, CNP, YIGSRG, mimetics of these, or combinations of these.

12. The block copolymer of claim 11, further comprising a sequence selected from RGD, cRGD, SIKVAV (SEQ ID NO:

2), CNP, YIGSRG, (SEQ ID NO;

     3), mimetics of these, or combinations of these.

13. The block copolymer of claim 1, wherein the biodegradable linkage is selected from poly(lactic acid) (PLA), poly(glycolic acid) (PLGA), polycaprolactone (PCL), poly(3-hydroxybutyric acid (PHB), poly(4-hydroxybutyrate (P4HB), or combinations of these.

14. A composition comprising the block copolymer of claim 1, and a cell.

15. A composition comprising the block copolymer of claim 2, and a cell.

16. The composition of claim 14, wherein the cell is stem cell.

17. The composition of claim 14, further comprising a pharmaceutically acceptable carrier.

18. The composition of claim 15, wherein the cell is a stem cell.

19. The composition of claim 15, further comprising a pharmaceutically acceptable carrier.

20. A medical device comprising a coating, the coating comprising the block copolymer of claim 1.

21. A medical device comprising a coating, the coating comprising the block copolymer of claim 2.

22. A medical device comprising a coating, the coating comprising the block copolymer of claim 3.

23. A medical device comprising a coating, the coating comprising the block copolymer of claim 4.

24. A medical device comprising a coating, the coating comprising the block copolymer of claim 5.

25. A medical device comprising a coating, the coating comprising the block copolymer of claim 6.

26. A medical device comprising a coating, the coating comprising the block copolymer of claim 7.

27. A medical device comprising a coating, the coating comprising the block copolymer of claim 8.

28. A medical device comprising a coating, the coating comprising the block copolymer of claim 9.

29. A medical device comprising a coating, the coating comprising the block copolymer of claim 10.

30. A medical device comprising a coating, the coating comprising the block copolymer of claim 11.

31. A medical device comprising a coating, the coating comprising the block copolymer of claim 12.

32. A medical device comprising a coating, the coating comprising the block copolymer of claim 13.

33. The medical device of claim 20, wherein the coating further comprises a bioactive agent.

34. The medical device of claim 33, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutase mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), γ

-hiridun, clobetasol, mometasone, pimecrolimus, imatinib mesylate, or midostaurin, or prodrugs, co-drugs, or combinations of these.

35. The medical device of claim 34, which is a stent.

36. The medical device of claim 34, which is a bioabsorbable stent.

37. A method of treating, preventing or ameliorating a medical condition, comprising providing a composition according to claim 14, and delivering the composition to a human having the medical condition.

38. A method of treating, preventing or ameliorating a medical condition, comprising providing a composition according to claim 15, and delivering the composition to a human having the medical condition.

39. The method of claim 37, wherein the medical condition pertains to an organ of the human.

40. The method of claim 39, wherein the organ is heart.

41. The method of claim 39, wherein the organ is blood vessel.

42. A method of treating, preventing or ameliorating a disorder in a patient comprising implanting in the patient the medical device of claim 33, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, urethra obstruction, tumor obstruction, diabetic vascular disease, and combinations thereof.

43. A method of treating, preventing or ameliorating a disorder in a patient comprising implanting in the patient the medical device of claim 34, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, urethra obstruction, tumor obstruction, diabetic vascular disease, and combinations thereof.